Lexicon Pharmaceuticals vs Scilex
LXRX and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and SCLX compare
Lexicon Pharmaceuticals is the larger company, worth 75 times as much as Scilex ($792M against $10.6M).
Scilex grew revenue faster over the last twelve months (−28.5% versus −29.0% for Lexicon Pharmaceuticals).
Lexicon Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −147% compared with −1470% at Scilex.
Lexicon Pharmaceuticals scores higher on the StockData Score (5 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | SCLX |
|---|---|---|
| Size and price | ||
| Market cap | $792M | $10.6M |
| Share price | $1.78 | $1.25 |
| Change, 1 year | 19.5% | −93.0% |
| Change, 5 years | −62.4% | −99.6% |
| Beta (5Y) | 0.01 | 2.18 |
| Employees | 81 | 34 |
| StockData Score | ||
| Total score | 5 (better) | 1 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 19.1× | 0.3× (better) |
| P/B | 4.5× | – |
| Fair value | $0.950 | – |
| Margin of safety | −87.4% | – |
| Growth | ||
| Revenue growth (TTM) | −29.0% | −28.5% (better) |
| Revenue growth, 5Y average | 15.7% (better) | 5.1% |
| Profitability | ||
| Gross margin | 99.1% | 161% (better) |
| Operating margin | −131% (better) | −1136% |
| Net margin | −147% (better) | −1470% |
| Return on equity | −40.2% | – |
| Return on invested capital | −163% | – |
| Financial health | ||
| Debt / equity | 0.29 | – |
| Interest coverage | – | −22.2× |
| Current ratio | 13.37 (better) | 0.07 |
| Altman Z-score | −4.87 (better) | −12.75 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 81.9% | 9.8% |
| Insider net buying, 12 months | $2.8M (better) | −$12.8M |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- SCLX stock overview
- SCLX income statement
- SCLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.